Madrigal (MDGL)
NASDAQ:MDGL
Want to see MDGL full AI Analyst Report?
MDGL Stock Chart & Stats
$532.02
-$1.78(-0.55%)
At close: 4:00 PM EST
$532.02
-$1.78(-0.55%)
Day’s Range― - ―
52-Week Range$276.67 - $615.00
Previous CloseN/A
Volume47.78K
Average Volume (3M)291.06K
Market Cap
$11.66B
Enterprise Value$11.64B
Total Cash (Recent Filing)$817.93M
Total Debt (Recent Filing)$347.31M
Price to Earnings (P/E)―
Beta0.26
Next Earnings
Aug 11, 2026EPS Estimate
-2.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.80
Shares Outstanding23,055,658
10 Day Avg. Volume287,409
30 Day Avg. Volume291,058
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)21.68
Price to Sales (P/S)13.63
P/FCF Ratio-68.75
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue10.28
Enterprise Value/Gross Profit11.04
Enterprise Value/Ebitda-41.41
Forecast
1Y Price Target
$648.82Price Target Upside21.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-6.55
Revenue Forecast (FY)$1.50B
Bulls Say, Bears Say
Bulls Say
Blockbuster Revenue GrowthSustained blockbuster sales and rapid patient adoption establish durable commercial scale, providing predictable product revenue to fund operations and pipeline investment. Large recurring prescription base reduces execution risk for U.S. commercialization and supports leverage of fixed infrastructure over time.
Very High Gross Margins / Strong Unit EconomicsExtremely high gross margins indicate attractive unit economics and pricing power, meaning incremental sales can drop to the bottom line once operating leverage and gross-to-net pressures normalize. This structural advantage supports long-term profitability potential as SG&A and R&D cadence stabilizes.
Diversified Pipeline And Milestone-driven CatalystsA broader pipeline and the ARO‑PNPLA3 siRNA entry materially diversify the company beyond a single product, creating multiple durable value drivers. Upcoming event-driven and histology readouts offer structural indication expansion opportunities that can extend lifetime revenue and reduce single-product concentration risk.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business still relies on financing or asset sales to sustain growth and fund trials. Even with improving trends, continuing cash burn constrains flexibility for sustained commercial investment or optionality for additional M&A without dilutive funding.
Rising Leverage Reduces Financial FlexibilityHigher debt relative to equity signals reduced balance-sheet optionality and increased fixed obligations. For a commercial-stage biotech still unprofitable, elevated leverage raises refinancing and covenant risks, limits the firm's ability to fund expensive trials or business development without costly or dilutive capital.
Material Gross-to-net Discounts And Royalty BurdenSustained mid-to-high 30% gross-to-net pressures and royalty obligations materially reduce realized revenue and margins versus gross sales. This structural drag lowers effective cash conversion on sales and compresses profit potential unless payor dynamics or contract structures improve long-term.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal’s price range in the past 12 months?
Madrigal lowest stock price was $276.67 and its highest was $615.00 in the past 12 months.
What is Madrigal’s market cap?
Madrigal’s market cap is $11.66B.
When is Madrigal’s upcoming earnings report date?
Madrigal’s upcoming earnings report date is Aug 11, 2026 which is in 51 days.
How were Madrigal’s earnings last quarter?
Madrigal released its earnings results on May 06, 2026. The company reported -$3.25 earnings per share for the quarter, beating the consensus estimate of -$4.23 by $0.98.
Is Madrigal overvalued?
According to Wall Street analysts Madrigal’s price is currently Undervalued.
Does Madrigal pay dividends?
Madrigal does not currently pay dividends.
What is Madrigal’s EPS estimate?
Madrigal’s EPS estimate is -2.58.
How many shares outstanding does Madrigal have?
Madrigal has 23,055,658 shares outstanding.
What happened to Madrigal’s price movement after its last earnings report?
Madrigal reported an EPS of -$3.25 in its last earnings report, beating expectations of -$4.23. Following the earnings report the stock price went up 7.415%.
Which hedge fund is a major shareholder of Madrigal?
Currently, no hedge funds are holding shares in MDGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$648.82 (21.95% Upside)
$648.82 (21.95% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 336.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $435.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
78.88%
12-Months-Change
Fundamentals
Return on Equity
-50.15%
Trailing 12-Months
Asset Growth
23.15%
Trailing 12-Months
Company Description
Madrigal
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive commercial and scientific momentum: Rezdiffra has achieved blockbuster status with rapid patient growth, a materially expanding addressable market, and an increasingly diverse pipeline (including a promising siRNA asset). These positives are balanced by elevated operating expenses, one‑time business development costs, a material gross‑to‑net discount, and near‑term non‑profitability with cash modestly reduced by strategic uses. Management emphasized durable long‑term opportunity, upcoming outcomes milestones (2027–2028), and disciplined, data‑driven pipeline advancement.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$648.82
▲(21.95% Upside)
Technical Analysis
Exelixis
―
Ionis Pharmaceuticals
―
Ascendis Pharma
―
BridgeBio Pharma
―
Roivant Sciences
―
Ownership Overview
17.99% Insiders
23.20% Mutual Funds
7.53% Other Institutional Investors
38.22% Public Companies and
Individual Investors